NASDAQ:HTGM - HTG Molecular Diagnostics Stock Price, Price Target & More

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) posted its quarterly earnings data on Thursday, May, 10th. The medical research company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.04. The medical research company had revenue of $4.16 million for the quarter, compared to the consensus estimate of $5.24 million. HTG Molecular Diagnostics had a negative return on equity of 338.96% and a negative net margin of 105.56%. View HTG Molecular Diagnostics' Earnings History.

2 Wall Street analysts have issued 1 year price targets for HTG Molecular Diagnostics' shares. Their predictions range from $7.00 to $7.00. On average, they expect HTG Molecular Diagnostics' stock price to reach $7.00 in the next twelve months. View Analyst Ratings for HTG Molecular Diagnostics.

Some companies that are related to HTG Molecular Diagnostics include Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT), Arrayit Corp common stock (ARYC), Aethlon Medical (AEMD), Precipio (PRPO), Pressure Biosciences (PBIO), Scientific Industries (SCND) and PositiveID (PSID).

(HTGM) raised $50 million in an initial public offering on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

News coverage about HTGM stock has trended positive on Monday, according to Accern Sentiment. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. HTG Molecular Diagnostics earned a coverage optimism score of 0.36 on Accern's scale. They also assigned media headlines about the medical research company an impact score of 45.50 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

HTG Molecular Diagnostics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include EAM Global Investors LLC (0.67%), Stifel Financial Corp (0.33%), Northern Trust Corp (0.18%) and New York State Common Retirement Fund (0.17%). Company insiders that own HTG Molecular Diagnostics stock include Holdings A/S Novo, Plc Glaxosmithkline and Shaun D Mcmeans. View Institutional Ownership Trends for HTG Molecular Diagnostics.

HTGM stock was purchased by a variety of institutional investors in the last quarter, including EAM Global Investors LLC, Stifel Financial Corp, Northern Trust Corp and New York State Common Retirement Fund. View Insider Buying and Selling for HTG Molecular Diagnostics.

Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HTGM stock can currently be purchased for approximately $3.28.

HTG Molecular Diagnostics has a market capitalization of $97.03 million and generates $14.76 million in revenue each year. The medical research company earns $-18,960,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. HTG Molecular Diagnostics employs 98 workers across the globe.

HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.